Answers are grounded in this paper and cite their sources.
Synthetic biology opens new avenues for developing and discovering natural products of therapeutic value in a sustainable manner. Traditional ‘grind and find’ bioactivity-guided fractionation approaches tend to pose challenges including rediscovery of known compounds, low production yields, and lack of ability to generate analogs for drug development. This perspective covers key examples of using synthetic biology strategies to overcome such barriers through generating difficult-to-source compounds, exploring the chemical space, harnessing next-generation hosts for improved synthesis, and modularizing the biosynthetic pathway for efficient manipulation and optimization. We highlight key examples of synthetic biology applied to develop therapeutically relevant natural products from the main classes of natural products: terpenes, polyketides, nonribosomal peptides, and ribosomally synthesized and posttranslationally synthesized peptides. Taken together, these new approaches provide access to complex and difficult-to-source natural products to develop next-generation medicines.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: